The latest from small and Emerging Pharma companies featuring Seaport Therapeutics, Avalyn Pharma & Hemab Therapeutics. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Seaport Announces $212-M IPO To Support Depression Treatments 
* Avalyn Pharma Seeking to Raise $300 M in IPO for Rare Respiratory Drug Programs 
* Hemab Announces $180-M IPO for Bleeding Disorder Drug 

---

Seaport Announces $212-M IPO To Support Depression Treatments 
Seaport Therapeutics, a Boston-based bio/pharmaceutical company developing treatments for depression, anxiety, and other neuropsychiatric disorders, has announced that it is seeking to raise $212 million in an initial public offering of 11.8 million shares of stock priced at $16 to $18 per share. Its lead candidate is GlyphAllo, an investigational oral prodrug of allopregnanolone for postpartum depression. A second product candidate, GlyphAgo, an oral prodrug of agomelatine, is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union with ongoing development globally.  

 Source: Seaport Therapeutics 

---

Avalyn Pharma Seeking to Raise $300 M in IPO for Rare Respiratory Drug Programs 
Avalyn Pharma, a Boston-based clinical-stage bio/pharmaceutical company focused on developing targeted therapies for rare lung diseases, is seeking to raise $300 million in an upsized initial public offering (IPO) of 16.6 million shares of its common stock at a price of $18.00 per share. The company raised is offering; it was initially seeking to raise $182 million in an IPO of 11.8 million shares of stock priced at $16 to $18 per share. The company’s lead candidate is AP01, an inhaled formulation of pirfenidone for treating progressive pulmonary fibrosis, a progressive lung disease.  

Source: Avalyn Pharma 

---

Hemab Announces $180-M IPO for Bleeding Disorder Drug 
Hemab Therapeutics, a Cambridge, Massachusetts-based clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders, has announced that it is seeking to raise $180 million in an initial public offering (IPO) of 11.8 million shares of common stock priced at $16.00 to $18.00 per share.  

The company’s lead asset is sutacimig (HMB-001), a bispecific antibody currently in Phase I/II clinical development for the prophylactic treatment of Glanzmann thrombasthenia, a rare inherited blood disorder, and Phase II clinical development for the prophylactic treatment of Factor VII deficiency, a rare inherited bleeding disorder. 

Source: Hemab Therapeutics